GeneDx Holdings Corp. (NASDAQ: WGS) Financial Performance and Market Position

Jefferies adjusted its price target for NASDAQ:WGS to $150, indicating a potential upside of 72.26%.GeneDx reported quarterly earnings of $0.14 per share, surpassing the Zacks Consensus Estimate by 27.27%.The company's revenues for Q4 2025 were $121 million, a significant increase from the previous year and above consensus estimates.GeneDx Holdings Corp. (NASDAQ:WGS) is a company based in Gaithersburg, Maryland, operating within the Zacks Medical Services industry. It focuses on providing genetic testing se ...